Election Results 2026 MidtermsView →
Dock Line
The beige tower and entrance canopy of Christus Santa Rosa Hospital in San Antonio, with palm trees in front, photographed in October 2012
Christus Santa Rosa Hospital in San Antonio, photographed in October 2012. File photo; the bills do not name this hospital. House Bill 1153, filed Nov. 13 by Rep. Barbara Gervin-Hawkins of District 120, and an identical Senate companion would bar certain health plans from imposing cost-sharing on screening mammograms and related breast imaging. (Billy Hathorn / Wikimedia Commons)

Jane Long

November 16, 2026 · 4 min read

Bills Would Bar Cost-Sharing for Mammograms and Follow-Up Breast Imaging

House Bill 1153, filed Nov. 13 by Rep. Barbara Gervin-Hawkins, and an identical Senate companion, SB 233, filed Nov. 9 by Sen. Carol Alvarado and four other senators, would bar certain health plans from imposing deductibles, coinsurance, or copayments on screening mammograms, diagnostic breast imaging, and supplemental breast examinations, beginning with plans issued or renewed on or after Jan. 1, 2028.

Rep. Barbara Gervin-Hawkins of District 120 filed a bill Friday that would bar certain health benefit plans from imposing a deductible, coinsurance, copayment, or similar out-of-pocket charge on coverage for a screening mammogram, diagnostic breast imaging, or a supplemental breast examination. The introduced text of House Bill 1153 is labeled "By: Gervin-Hawkins." The House bill history records the last action as "H Filed" on Nov. 13 and lists Senate Bill 233 as an identical companion. The Senate measure was filed Nov. 9 by Sen. Carol Alvarado of District 6, with Sens. Molly Cook, Gutierrez, Menéndez, and Rehmet also listed as authors. Both bills share council document 90R 2679 MEW-F, and the operative text of the two introduced versions is the same. The Texas House lists Gervin-Hawkins as the member from District 120. The filings are proposals for the 2027 session, not adopted law.

The bill would amend Insurance Code Chapter 1356. It would define a "cost-sharing requirement" as "a deductible, coinsurance, or copayment or a maximum limitation on the application of a deductible, coinsurance, or copayment or similar out-of-pocket expense." Amended Section 1356.005(b) would then provide: "A health benefit plan may not impose a cost-sharing requirement on coverage for a screening mammogram, diagnostic imaging, or supplemental breast examination." The introduced text would strike the present subsection's language that coverage required by the section "may not be less favorable than coverage for other radiological examinations under the plan" and "must be subject to the same dollar limits, deductibles, and coinsurance factors as coverage for other radiological examinations under the plan." This report does not independently restate the rest of Chapter 1356 from the official statutes site, which was not used, and does not list which plans fall under the chapter beyond the bill's caption, which refers to "certain health benefit plans."

The bill would also broaden what counts as "diagnostic imaging." Under the introduced text, that term would mean "a medically necessary and appropriate examination of the breast, as determined by National Comprehensive Cancer Network guidelines," including an examination using contrast-enhanced mammography, diagnostic mammography, breast ultrasound imaging, breast magnetic resonance imaging, or molecular breast imaging, that is designed to evaluate one of four situations: a subjective or objective abnormality detected by a physician or patient in a breast; an abnormality seen by a physician on a screening mammogram; an abnormality previously identified by a physician as probably benign in a breast for which follow-up imaging is recommended by a physician; or "an individual with a personal history of breast cancer or dense breast tissue." The strikeout in the introduced text shows that the present definition is limited to "an imaging examination of the breast, including an examination using diagnostic mammography, breast ultrasound imaging, or magnetic resonance imaging," without the National Comprehensive Cancer Network standard, contrast-enhanced mammography, molecular breast imaging, or the four evaluation categories. This report does not summarize the National Comprehensive Cancer Network guidelines, which were not read.

A new definition of "supplemental breast examination" would sit beside that diagnostic-imaging test. It would mean "a medically necessary and appropriate examination of the breast, as determined by National Comprehensive Cancer Network guidelines," including an examination using contrast-enhanced mammography, breast ultrasound imaging, breast magnetic resonance imaging, or molecular breast imaging, that is "used to screen for breast cancer when an abnormality has not been seen or suspected by a physician" and is "based on a patient's personal or family medical history or other factors that increase the patient's risk of breast cancer, including heterogeneously or extremely dense breasts." The two definitions are not the same. Diagnostic imaging, as the bill would write it, is built around an abnormality, a prior "probably benign" finding, or a personal history of breast cancer or dense breast tissue. A supplemental examination would be used when a physician has not seen or suspected an abnormality, and it would be tied to personal or family history or other risk factors, including dense breasts.

If, before implementing any provision, a state agency determined that a waiver or authorization from a federal agency was necessary, the agency affected by the provision "shall request the waiver or authorization and may delay implementing that provision until the waiver or authorization is granted." The bill does not name the federal agency or the program that might require that step.

The act would take effect Sept. 1, 2027, but it would apply only to a health benefit plan "that is delivered, issued for delivery, or renewed on or after January 1, 2028." A plan delivered, issued for delivery, or renewed before that date "is governed by the law as it existed immediately before the effective date of this Act, and that law is continued in effect for that purpose." The filings do not appropriate money, set a premium impact, or estimate how many screening mammograms, diagnostic examinations, or supplemental examinations would be affected.